stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) Return on equity
Zai Lab Limited Unsponsored ADR's return on equity over the twelve months to 30 September 2026 was −30.0%, down 7.4 percentage points from fiscal 2025 (−22.6%). Over the past ten years it has ranged from −71.5% (fiscal 2019) to 107.3% (fiscal 2016); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −22.6% | 8.85 |
| FY2024 | −31.4% | 4.93 |
| FY2023 | −36.3% | 0.21 |
| FY2022 | −36.6% | 18.72 |
| FY2021 | −55.3% | (18.53) |
| FY2020 | −36.7% | 34.75 |
| FY2019 | −71.5% | (14.29) |
| FY2018 | −57.2% | (2.32) |
| FY2017 | −54.9% | (162.18) |
| FY2016 | 107.3% | 55.75 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ADMA ADMA Biologics Inc compare | 42.0% |
| XNCR Xencor, Inc. compare | −29.1% |
| ZLAB Zai Lab Limited Unsponsored ADR | −30.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −30.2% |
| MBX MBX Biosciences, Inc. compare | −33.2% |
| CLDX Celldex Therapeutics, Inc. compare | −43.9% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −48.7% |
| PHVS Pharvaris N.V. compare | −71.5% |
| RCUS Arcus Biosciences, Inc. compare | −114.1% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ZLAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement